NASDAQ:CORT Corcept Therapeutics - CORT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. $21.66 +0.03 (+0.14%) (As of 03/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$21.58▼$21.9350-Day Range$19.20▼$24.4752-Week Range$17.19▼$30.14Volume1.17 million shsAverage Volume782,708 shsMarket Capitalization$2.34 billionP/E Ratio24.61Dividend YieldN/APrice Target$28.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Corcept Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside31.6% Upside$28.50 Price TargetShort InterestN/ADividend StrengthN/ASustainability-1.06Upright™ Environmental ScoreNews Sentiment1.12Based on 8 Articles This WeekInsider TradingN/AProj. Earnings Growth-4.71%From $0.85 to $0.81 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.45 out of 5 starsMedical Sector175th out of 1,004 stocksPharmaceutical Preparations Industry75th out of 489 stocks 3.3 Analyst's Opinion Consensus RatingCorcept Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.50, Corcept Therapeutics has a forecasted upside of 31.6% from its current price of $21.66.Amount of Analyst CoverageCorcept Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for CORT. Previous Next 0.0 Dividend Strength Dividend YieldCorcept Therapeutics does not currently pay a dividend.Dividend GrowthCorcept Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCorcept Therapeutics has received a 68.71% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sex hormones and modulators of the genital system (G03)", "Clinical research services for metabolic diseases", and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Corcept Therapeutics is -1.06. Previous Next 2.8 News and Social Media Coverage News SentimentCorcept Therapeutics has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Corcept Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 4 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corcept Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders18.60% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions80.08% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Corcept Therapeutics are expected to decrease by -4.71% in the coming year, from $0.85 to $0.81 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corcept Therapeutics is 24.61, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.97.Price to Earnings Ratio vs. SectorThe P/E ratio of Corcept Therapeutics is 24.61, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 126.59.Price to Book Value per Share RatioCorcept Therapeutics has a P/B Ratio of 4.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Corcept Therapeutics (NASDAQ:CORT) StockCorcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.Read More Receive CORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CORT Stock News HeadlinesMarch 31, 2023 | finance.yahoo.comJazz (JAZZ) Up 0.4% Since Last Earnings Report: Can It Continue?March 30, 2023 | finance.yahoo.comWhy Is Corcept (CORT) Up 9.6% Since Last Earnings Report?April 1, 2023 | Investorplace Media (Ad)5 Stocks to Buy ImmediatelyAmerica’s #1 stock picker issues 5 buy alerts – one of which is positioned to be the next Tesla. Just click to claim your copy. March 28, 2023 | finance.yahoo.comCorcept Therapeutics Initiates CATALYST Clinical TrialMarch 27, 2023 | finance.yahoo.comCorcept Therapeutics (NASDAQ:CORT) stock performs better than its underlying earnings growth over last three yearsMarch 8, 2023 | markets.businessinsider.comAnalyst Expectations for Corcept Therapeutics's FutureMarch 6, 2023 | finance.yahoo.comCorcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 7,500,000 Shares of its Common StockMarch 3, 2023 | finance.yahoo.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Q4 2022 Earnings Call TranscriptApril 1, 2023 | Investorplace Media (Ad)5 Stocks to Buy ImmediatelyAmerica’s #1 stock picker issues 5 buy alerts – one of which is positioned to be the next Tesla. Just click to claim your copy. March 2, 2023 | finance.yahoo.comCorcept Therapeutics Full Year 2022 Earnings: EPS Misses ExpectationsMarch 1, 2023 | finance.yahoo.comQ4 2022 Corcept Therapeutics Inc Earnings CallMarch 1, 2023 | finance.yahoo.comCorcept's (CORT) Q4 Earnings and Revenues Miss EstimatesFebruary 28, 2023 | apnews.comCorcept: Q4 Earnings SnapshotFebruary 28, 2023 | msn.comCorcept Therapeutics GAAP EPS of $0.15 misses by $0.08, revenue of $103M misses by $2.08MFebruary 28, 2023 | finance.yahoo.comCorcept Therapeutics Announces Fourth Quarter and Full-Year 2022 Audited Financial Results and Provides Corporate UpdateFebruary 24, 2023 | finance.yahoo.comWith 71% ownership of the shares, Corcept Therapeutics Incorporated (NASDAQ:CORT) is heavily dominated by institutional ownersFebruary 15, 2023 | msn.comBenzinga's Top Ratings Upgrades, Downgrades For February 15, 2023February 14, 2023 | finance.yahoo.comCorcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference CallFebruary 13, 2023 | nasdaq.comRenaissance Technologies Cuts Stake in Corcept Therapeutics (CORT)February 13, 2023 | finance.yahoo.comCorcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action LitigationJanuary 24, 2023 | finance.yahoo.comEstimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)January 17, 2023 | finance.yahoo.comCorcept (CORT) Rides on Robust Korlym Sales, High Reliance a WoeJanuary 11, 2023 | finance.yahoo.comDurect (DRRX) Soars 11.8%: Is Further Upside Left in the Stock?January 8, 2023 | seekingalpha.comCorcept Therapeutics: Korlym Overhang Appears To Be A Drag On Valuation UpsideJanuary 1, 2023 | benzinga.comROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation - CORTDecember 29, 2022 | finance.yahoo.comCorcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?December 28, 2022 | marketwatch.comEQUITY ALERT: Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Class Action Investigation – CORTSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CORT Company Calendar Last Earnings2/28/2023Today3/31/2023Next Earnings (Estimated)5/04/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:CORT CUSIP21835210 CIK1088856 Webwww.corcept.com Phone(650) 327-3270Fax650-327-3218Employees238Year Founded1998Price Target and Rating Average Stock Price Forecast$28.50 High Stock Price Forecast$32.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+31.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.88 Trailing P/E Ratio24.61 Forward P/E Ratio25.48 P/E GrowthN/ANet Income$101.42 million Net Margins25.21% Pretax Margin28.91% Return on Equity22.20% Return on Assets19.47% Debt Debt-to-Equity RatioN/A Current Ratio6.89 Quick Ratio6.80 Sales & Book Value Annual Sales$401.86 million Price / Sales5.82 Cash Flow$0.96 per share Price / Cash Flow22.56 Book Value$4.66 per share Price / Book4.65Miscellaneous Outstanding Shares107,900,000Free Float87,830,000Market Cap$2.34 billion OptionableOptionable Beta0.48 Social Links Key ExecutivesJoseph K. BelanoffPresident, Chief Executive Officer & DirectorAtabak MokariChief Financial OfficerHazel HuntChief Scientific OfficerSean MaduckPresident-Corcept EndocrinologyWilliam GuyerChief Development OfficerKey CompetitorsSupernus PharmaceuticalsNASDAQ:SUPNPacira BioSciencesNASDAQ:PCRXPerrigoNYSE:PRGOJazz PharmaceuticalsNASDAQ:JAZZInsmedNASDAQ:INSMView All CompetitorsInsiders & InstitutionsNeo Ivy Capital ManagementBought 22,255 shares on 3/27/2023Ownership: 0.021%Voya Investment Management LLCBought 791 shares on 2/28/2023Ownership: 0.108%Teachers Retirement System of The State of KentuckySold 2,073 shares on 2/22/2023Ownership: 0.027%Truist Financial CorpBought 22,537 shares on 2/17/2023Ownership: 0.021%Point72 Middle East FZEBought 5,258 shares on 2/16/2023Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions CORT Stock - Frequently Asked Questions Should I buy or sell Corcept Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CORT shares. View CORT analyst ratings or view top-rated stocks. What is Corcept Therapeutics' stock price forecast for 2023? 4 equities research analysts have issued twelve-month price targets for Corcept Therapeutics' stock. Their CORT share price forecasts range from $22.00 to $32.00. On average, they expect the company's share price to reach $28.50 in the next twelve months. This suggests a possible upside of 31.6% from the stock's current price. View analysts price targets for CORT or view top-rated stocks among Wall Street analysts. How have CORT shares performed in 2023? Corcept Therapeutics' stock was trading at $20.31 at the beginning of the year. Since then, CORT shares have increased by 6.6% and is now trading at $21.66. View the best growth stocks for 2023 here. When is Corcept Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023. View our CORT earnings forecast. How were Corcept Therapeutics' earnings last quarter? Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its quarterly earnings results on Tuesday, February, 28th. The biotechnology company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.23 by $0.09. The biotechnology company had revenue of $103.06 million for the quarter, compared to analysts' expectations of $106.93 million. Corcept Therapeutics had a net margin of 25.21% and a trailing twelve-month return on equity of 22.20%. The business's quarterly revenue was up 4.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.26 earnings per share. What ETFs hold Corcept Therapeutics' stock? ETFs with the largest weight of Corcept Therapeutics (NASDAQ:CORT) stock in their portfolio include Invesco Dynamic Pharmaceuticals ETF (PJP), The Acquirers Fund (ZIG), Invesco S&P SmallCap Health Care ETF (PSCH), Janus Henderson Small Cap Growth Alpha ETF (JSML), First Trust Nasdaq Pharmaceuticals ETF (FTXH), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Pharmaceuticals ETF (XPH) and Invesco S&P SmallCap Quality ETF (XSHQ). What guidance has Corcept Therapeutics issued on next quarter's earnings? Corcept Therapeutics issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $430.00 million-$450.00 million, compared to the consensus revenue estimate of $434.79 million. What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO? 6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Corcept Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI). What is Corcept Therapeutics' stock symbol? Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT." Who are Corcept Therapeutics' major shareholders? Corcept Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (6.77%), Ingalls & Snyder LLC (6.34%), Parallel Advisors LLC (3.46%), Dimensional Fund Advisors LP (1.94%), Boston Trust Walden Corp (1.72%) and Geode Capital Management LLC (1.60%). Insiders that own company stock include Daniel N Swisher Jr, G Leonard Baker Jr, G Leonard Baker, Jr, Gary Charles Robb, Joseph Douglas Lyon, Joseph K Belanoff and Sean Maduck. View institutional ownership trends. How do I buy shares of Corcept Therapeutics? Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Corcept Therapeutics' stock price today? One share of CORT stock can currently be purchased for approximately $21.66. How much money does Corcept Therapeutics make? Corcept Therapeutics (NASDAQ:CORT) has a market capitalization of $2.34 billion and generates $401.86 million in revenue each year. The biotechnology company earns $101.42 million in net income (profit) each year or $0.88 on an earnings per share basis. How many employees does Corcept Therapeutics have? The company employs 238 workers across the globe. How can I contact Corcept Therapeutics? Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The official website for the company is www.corcept.com. The biotechnology company can be reached via phone at (650) 327-3270, via email at cjames@corcept.com, or via fax at 650-327-3218. This page (NASDAQ:CORT) was last updated on 4/1/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.